Core Insights - MindWalk Holdings Corp. has made a significant advancement in its AI-designed GLP-1 therapeutics program, revealing a new connection between GLP-1 biology and a non-overlapping pathway related to healthy aging and systemic resilience [1] Company Developments - The insights were derived from the company's LensAl platform, supporting the development of a first-in-class dual-pathway regimen [1]